Background The Ad26.COV2.S vaccine is a recombinant, replication-incompetent human
adenovirus type 26 vector encoding full-length severe acute respiratory syndrome coronavirus …

Dengue virus is a single-stranded, enveloped RNA virus that productively infects human
dendritic cells (DCs) primarily at the immature stage of their differentiation. We now find that all …

Background REGEN-COV (previously known as REGN-COV2), a combination of the monoclonal
antibodies casirivimab and imdevimab, has been shown to markedly reduce the risk of …

Dengue virus (DV), an arthropod-borne flavivirus, causes a febrile illness for which there is
no antiviral treatment and no vaccine 1, 2. Macrophages are important in dengue …

Background The Ad26.COV2.S vaccine was highly effective against severe–critical coronavirus
disease 2019 (Covid-19), hospitalization, and death in the primary phase 3 efficacy …

Preclinical studies of human immunodeficiency virus type 1 (HIV-1) vaccine candidates
have typically shown post-infection virological control, but protection against acquisition of …

A wide range of microorganisms can replicate in macrophages, and cell entry of these
pathogens via non-neutralising IgG antibody complexes can result in increased intracellular …

Leishmaniasis, a vector-borne parasitic disease, is transmitted during a sandfly blood meal
as the parasite is delivered into the dermis. The parasite displays a unique immune evasion …

Importance Easy-to-administer anti–SARS-CoV-2 treatments may be used to prevent
progression from asymptomatic infection to symptomatic disease and to reduce viral carriage. …

Dengue viruses (DV), composed of four distinct serotypes (DV1 to DV4), cause 50 to 100
million infections annually. Durable homotypic immunity follows infection but may predispose to …